Skip to main content
← All Services

Target Product Profiles & Platform Target Profiles

If you do not know where you are going, how do you get there? A Target Product Profile answers that question. It defines what your drug should look like at market approval and serves as the foundation of every successful development program.

What Is a Target Product Profile?

A Target Product Profile (TPP) is a strategic document that describes the desired characteristics of a drug product at market approval. It serves as the north star for your entire development program.

A TPP clarifies the disease or disorder you intend to treat, the patient population, mechanism of action, efficacy and safety profile, administration method, quality standards, go/no-go criteria, and evidence gaps. Every one of these elements drives a decision. Every decision shapes your roadmap.

Like a fine wine that must age to reach maturity, a TPP becomes more refined as you generate more data and insights into your desired patient population. It starts as a hypothesis. It matures into a navigation tool.

What Is a Platform Target Profile?

A Platform Target Profile (PTP) defines the desired characteristics of a drug delivery system or personalized therapy platform, rather than a single drug product. Where a TPP describes one product, a PTP describes the technology engine that can generate multiple products.

PTPs matter for teams building gene therapy vectors, nanoparticle delivery systems, cell therapy platforms, or personalized medicine approaches. The PTP captures scalability parameters, manufacturing consistency, personalization criteria, and the regulatory pathway for platform-level characterization.

Most emerging biopharma teams need both. The PTP defines the platform. The TPP defines each product that runs on that platform. Together, they create clarity for your team, your investors, and your regulators.

Anatomy of a TPP

What a Target Product Profile actually looks like

Every attribute is a decision. Some you make at the start; others mature with the data. The sheet below is illustrative — yours is built around your candidate.

Target Product Profile

Sample — Anatomy of a TPP

Indication

Drug-resistant tuberculosis (MDR-TB)

Sample case — illustrative only

Patient Population

Adults, treatment-refractory, HIV co-infection permitted

Mechanism of Action

Inhibitor of mycobacterial ATP synthase

Route of Administration

Oral, once-daily

Efficacy Endpoint

≥85% culture conversion at 8 weeks

vs. standard-of-care baseline ~60%

Safety / Tolerability

No grade ≥3 hepatotoxicity; QTc Δ < 30ms at therapeutic dose

Manufacturing
Pending discoveryManufacturing — pending discovery during the engagement
Commercial Positioning
Pending discoveryCommercial Positioning — pending discovery during the engagement

Living document

Refined with each data milestone — Discovery → Phase I

Illustrative sample. Your TPP is built around your candidate, your patient population, and your strategic choices.

Strategic Value of a TPP

Without a TPP, teams make decisions in silos. Chemistry sets one target, clinical sets another, regulatory expects something else. The result is a misaligned program that wastes time and capital. A strong TPP prevents that.

Forces Explicit Choices

No ambiguity. Every stakeholder sees the same target efficacy, the same safety thresholds, the same patient population.

Sets Go/No-Go Criteria

Defines the evidence thresholds that determine whether your program advances or pivots. No more guessing.

Aligns All Planning

R&D, clinical, regulatory, commercial. One document aligns every function around a single achievable vision of success.

Sharpens Investor Narrative

Investors fund clarity. A rigorous TPP demonstrates that your team knows the destination and the roadmap to reach it.

Living Document

The TPP evolves as new evidence emerges. It absorbs data, closes gaps, and sharpens with every development milestone.

Key Components of a TPP & PTP

Six domains define a complete profile. The first five apply to every TPP. The sixth addresses platform-specific elements for PTPs.

Indication & Population

  • Target disease or disorder
  • Patient population definition
  • Unmet medical need and evidence gaps
  • Epidemiology and burden of illness

Efficacy & Safety

  • Primary efficacy endpoints
  • Minimum acceptable efficacy thresholds
  • Safety and tolerability profile
  • Risk-benefit assessment framework

Product Characteristics

  • Dosage form and route of administration
  • Dosing regimen and compliance factors
  • Shelf life, storage, and quality standards
  • Manufacturing and scalability considerations

Regulatory & Commercial

  • Regulatory classification and pathway
  • Label claim objectives
  • Competitive differentiation and positioning
  • Pricing, reimbursement, and market access

Clinical Development

  • Phase I through III design alignment
  • Biomarker strategy and endpoint justification
  • Comparator selection rationale
  • Go/no-go criteria at each stage gate

Platform-Specific (PTP)

  • Platform characterization and mechanism
  • Scalability and manufacturing consistency
  • Personalization criteria and adaptability
  • Technology differentiation across indications

Frequently Asked Questions

Define Your Product's Journey

Whether you are building your first TPP, developing a PTP for a platform technology, or refining an existing profile, we bring the clarity and execution rigor to get it right.

Book a Free Strategy Call